Cali F Bartholomeusz1,2,3, Vanessa L Cropley3, Cassandra Wannan1,2,3, Maria Di Biase3, Patrick D McGorry1,2, Christos Pantelis3,4. 1. 1 Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia. 2. 2 Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. 3. 3 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia. 4. 4 Centre for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton South, VIC, Australia.
Abstract
OBJECTIVE: This review critically examines the structural neuroimaging evidence in psychotic illness, with a focus on longitudinal imaging across the first-episode psychosis and ultra-high-risk of psychosis illness stages. METHODS: A thorough search of the literature involving specifically longitudinal neuroimaging in early illness stages of psychosis was conducted. The evidence supporting abnormalities in brain morphology and altered neurodevelopmental trajectories is discussed in the context of a clinical staging model. RESULTS: In general, grey matter (and, to a lesser extent, white matter) declines across multiple frontal, temporal (especially superior regions), insular and parietal regions during the first episode of psychosis, which has a steeper trajectory than that of age-matched healthy counterparts. Although the ultra-high-risk of psychosis literature is considerably mixed, evidence indicates that certain volumetric structural aberrations predate psychotic illness onset (e.g. prefrontal cortex thinning), while other abnormalities present in ultra-high-risk of psychosis populations are potentially non-psychosis-specific (e.g. hippocampal volume reductions). CONCLUSION: We highlight the advantages of longitudinal designs, discuss the implications such studies have on clinical staging and provide directions for future research.
OBJECTIVE: This review critically examines the structural neuroimaging evidence in psychotic illness, with a focus on longitudinal imaging across the first-episode psychosis and ultra-high-risk of psychosis illness stages. METHODS: A thorough search of the literature involving specifically longitudinal neuroimaging in early illness stages of psychosis was conducted. The evidence supporting abnormalities in brain morphology and altered neurodevelopmental trajectories is discussed in the context of a clinical staging model. RESULTS: In general, grey matter (and, to a lesser extent, white matter) declines across multiple frontal, temporal (especially superior regions), insular and parietal regions during the first episode of psychosis, which has a steeper trajectory than that of age-matched healthy counterparts. Although the ultra-high-risk of psychosis literature is considerably mixed, evidence indicates that certain volumetric structural aberrations predate psychotic illness onset (e.g. prefrontal cortex thinning), while other abnormalities present in ultra-high-risk of psychosis populations are potentially non-psychosis-specific (e.g. hippocampal volume reductions). CONCLUSION: We highlight the advantages of longitudinal designs, discuss the implications such studies have on clinical staging and provide directions for future research.
Entities:
Keywords:
Neuroimaging; clinical staging; early psychosis; longitudinal trajectory; schizophrenia spectrum
Authors: Maria Angelique Di Biase; Vanessa L Cropley; Luca Cocchi; Alexander Fornito; Fernando Calamante; Eleni P Ganella; Christos Pantelis; Andrew Zalesky Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Nikolaos Koutsouleris; Lana Kambeitz-Ilankovic; Stephan Ruhrmann; Marlene Rosen; Anne Ruef; Dominic B Dwyer; Marco Paolini; Katharine Chisholm; Joseph Kambeitz; Theresa Haidl; André Schmidt; John Gillam; Frauke Schultze-Lutter; Peter Falkai; Maximilian Reiser; Anita Riecher-Rössler; Rachel Upthegrove; Jarmo Hietala; Raimo K R Salokangas; Christos Pantelis; Eva Meisenzahl; Stephen J Wood; Dirk Beque; Paolo Brambilla; Stefan Borgwardt Journal: JAMA Psychiatry Date: 2018-11-01 Impact factor: 21.596
Authors: Carolina Makowski; John D Lewis; Claude Lepage; Ashok K Malla; Ridha Joober; Martin Lepage; Alan C Evans Journal: Cereb Cortex Date: 2019-12-17 Impact factor: 5.357
Authors: Jun Konishi; Elisabetta C Del Re; Sylvain Bouix; Gabriëlla A M Blokland; Raquelle Mesholam-Gately; Kristen Woodberry; Margaret Niznikiewicz; Jill Goldstein; Yoshio Hirayasu; Tracey L Petryshen; Larry J Seidman; Martha E Shenton; Robert W McCarley Journal: Brain Imaging Behav Date: 2018-08 Impact factor: 3.978
Authors: Suzanne N Avery; Kristan Armstrong; Jennifer U Blackford; Neil D Woodward; Neal Cohen; Stephan Heckers Journal: Schizophr Res Date: 2019-08-08 Impact factor: 4.939
Authors: Tara A Niendam; Kimberly L Ray; Ana-Maria Iosif; Tyler A Lesh; Stefania R Ashby; Pooja K Patel; Jason Smucny; Emilio Ferrer; Marjorie Solomon; J Daniel Ragland; Cameron S Carter Journal: JAMA Psychiatry Date: 2018-12-01 Impact factor: 21.596
Authors: Suzanne N Avery; Kristan Armstrong; Maureen McHugo; Simon Vandekar; Jennifer Urbano Blackford; Neil D Woodward; Stephan Heckers Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306